Génomique
July 21, 2026
When a global biopharmaceutical company needed to replace an obsolete qPCR-based patient-selection assay for a Phase 3 cancer trial, speed was essential, but speed alone was not sufficient.
CellCarta and Pillar Biosciences responded with an integrated development model that ran assay design, clinical validation, regulatory documentation, and laboratory implementation as parallel workstreams rather than sequential ones.
The result: a validated, trial-ready FGFR NGS patient-selection assay delivered in less than six months! Cutting the standard 10–12 month process nearly in half and keeping the sponsor’s first-patient enrollment timeline on track.
